Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| | 10-K | 8-K | 10-K | 8-K | 10-K | 10-K/A | 10-K | 10-K |
| Revenues: |
| Japan | 9.8 | | 2.3 | | 19.8 | | 100.0 | |
| AstraZeneca | | | | | | | | 111.3 |
| Other | 131.0 | | 233.0 | | 156.5 | | 113.0 | 19.6 |
| Total revenues [+] | 140.7 | 140.7 | 235.3 | 235.3 | 176.3 | 256.6 | 213.0 | 131.0 |
| Licensing | | 22.6 | | 116.4 | | | | |
| Products | | 82.9 | | 47.6 | | | | |
| Revenue growth [+] | -40.2% | -40.2% | 33.5% | | -31.3% | 20.5% | 62.6% | -28.5% |
| Japan | 323.6% | | -88.4% | | | | | |
| AstraZeneca | | | | | | | | -26.8% |
| Europe | | | | | | 29.0% | 1.9% | -26.9% |
| Cost of goods sold | 441.8 | 20.3 | 463.8 | 12.9 | 368.2 | 1.1 | 0.0 | 0.0 |
| Gross profit | -301.0 | 120.5 | -228.5 | 222.4 | -191.9 | 255.4 | 213.0 | 131.0 |
| Gross margin | -213.9% | 85.6% | -97.1% | 94.5% | -108.8% | 99.6% | 100.0% | 100.0% |
| Selling, general and administrative | | 124.7 | 60.0 | 123.9 | | 135.5 | 63.8 | 51.8 |
| Research and development | | 296.8 | | 387.0 | | 209.3 | 235.8 | 196.5 |
| Other operating expenses | -13.8 | | -56.8 | | -8.7 | | | |
| EBITDA [+] | | | | | | -78.2 | -80.1 | -111.2 |
| EBITDA growth | 24.0% | 4.3% | 26.5% | | 134.3% | -2.5% | -27.9% | 152.7% |
| EBITDA margin | -204.1% | -213.9% | -98.5% | -122.6% | -103.9% | -30.5% | -37.6% | -84.9% |
| Depreciation and amortization | | | | | | 11.1 | 6.6 | 6.1 |
| EBIT [+] | -287.3 | -301.0 | -231.8 | -288.5 | -183.2 | -89.3 | -86.7 | -117.3 |
| EBIT growth | 24.0% | 4.3% | 26.5% | | 105.1% | 3.0% | -26.1% | 134.4% |
| EBIT margin | -204.1% | -213.9% | -98.5% | -122.6% | -103.9% | -34.8% | -40.7% | -89.5% |
| Non-recurring items | | | 60.0 | | | | | |
| Interest expense | | 1.4 | | 1.1 | | 2.9 | 11.0 | 9.7 |
| Interest expense | 1.4 | 1.4 | 1.1 | 1.1 | 2.4 | 2.9 | 11.0 | 9.7 |
| Other income (expense), net | -6.2 | 7.6 | 2.2 | -1.1 | -3.2 | 15.5 | 11.6 | 6.4 |
| Pre-tax income | -294.9 | -294.9 | -290.7 | -290.7 | -188.7 | -76.6 | -86.1 | -120.6 |
| Income taxes | 0.4 | 0.4 | 0.3 | 0.3 | 0.4 | 0.3 | 0.3 | 0.3 |
| Tax rate | | | | | | | | |
| Net income | -293.7 | -293.7 | -290.0 | -290.0 | -189.3 | -77.0 | -86.4 | -120.9 |
| Net margin | -208.7% | -208.7% | -123.3% | -123.3% | -107.4% | -30.0% | -40.6% | -92.3% |
| |
| Basic EPS [+] | ($3.14) | ($3.14) | ($3.14) | ($3.14) | ($2.11) | ($0.89) | ($1.03) | ($1.66) |
| Growth | -0.1% | -0.1% | 49.1% | | 137.1% | -13.6% | -37.9% | 78.9% |
| Diluted EPS [+] | ($3.14) | ($3.14) | ($3.14) | ($3.14) | ($2.11) | ($0.89) | ($1.03) | ($1.66) |
| Growth | -0.1% | -0.1% | 49.1% | | 137.1% | -13.6% | -37.9% | 78.9% |
| |
| Shares outstanding (basic) [+] | 93.6 | 93.6 | 92.3 | 92.3 | 89.9 | 86.6 | 84.1 | 73.0 |
| Growth | 1.3% | 1.3% | 2.8% | | 3.7% | 3.1% | 15.2% | 16.3% |
| Shares outstanding (diluted) [+] | 93.6 | 93.6 | 92.3 | 92.3 | 89.9 | 86.6 | 84.1 | 73.0 |
| Growth | 1.3% | 1.3% | 2.8% | | 3.7% | 3.1% | 15.2% | 16.3% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|